Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV

Executive Summary

FDA advisory committee votes 7-6 that the strong efficacy profile of Solithera (solithromycin) outweighs its unknown safety risks; panels agreed that more data was needed, but were split on whether it was needed pre- or post-approval.

Advertisement

Related Content

NIH Funding Boost Underscores Tensions Between Trump, Congress
Antibiotic Development: Limited Population Pathway In US Removes Barrier
US FDA Advisory Committee Drought Is Over … Unless Sponsors Are Scared Of Dark Clouds
Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Rx For Industry: Key Provisions Of The 21st Century Cures Act
Antibiotic Development: ‘Wildcard Exclusivity’ Proposal Returns
Advisory Committee Recommendations Could Limit Use Of Solithera
Cempra To Defend CABP Antibiotic's Safety At US FDA Advisory Panel

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel